fibromyalgia

Governor John Carney (D) signed HB 285 into law, expanding medical cannabis access in Delaware. The new legislation, effective immediately, allows physicians to recommend medical cannabis to any patient who might benefit, without the need for a state-specific qualifying condition. Additionally,...

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase 1 For IV Psilocin First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused...

Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly advancing through analytical testing and preclinical trials toward determining drug release and stability following approval by state and federal authorities....

New research has shown that medical cannabis may effectively manage fibromyalgia and associated symptoms of depression and anxiety. MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) said the study was conducted by its subsidiary Harvest Medicine. Titled "Self-Reported Effects of...

Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.  The new project includes...

People who live with the pain, nausea, anxiety, depression and other symptoms of fibromyalgia also live with the sad fact that there’s no cure and not a single drug to treat this condition that affects 3% to 5% of the world's population and 3.5 million people in ...

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. Filament To Begin Phase 2 Study On Botanical Psilocybin Drug For Meth Use Disorder Clinical-stage natural psychedelic drug developer Filament Health Corp. (...

Living with fibromyalgia is challenging and painful. Those suffering from this illness also experience fatigue and cognitive difficulties that can provoke unpleasant ups and downs. A disorder that affects women twice as often as men thankfully can be treated with cannabis. A recent study...

Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begun dosing in its IND-enabling study of proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia.  This safety evaluation trial will be conducted by Experimur, a...

Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding psilocybin-based TRP-8803 development’s IP.   Tryp's Psilocybin-For-...

Following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) will stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for fibromyalgia. The...

NeuroMetrix Inc's (NASDAQ: NURO) Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults. Fibromyalgia is a common form of chronic pain accompanied by fatigue, sleep, cognitive and mood disturbances.  Quell is a wearable...

After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission is currently anticipated in the fourth quarter of 2022, pending completion of...

Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia. The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep,...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102 SL tablet for the management of fibromyalgia. Fibromyalgia is a disorder characterized by widespread...